Citius Pharmaceuticals Inc (CTXR) - Total Liabilities
Based on the latest financial reports, Citius Pharmaceuticals Inc (CTXR) has total liabilities worth $46.92 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Citius Pharmaceuticals Inc cash conversion from operations to assess how effectively this company generates cash.
Citius Pharmaceuticals Inc - Total Liabilities Trend (2011–2025)
This chart illustrates how Citius Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Citius Pharmaceuticals Inc's assets to evaluate the company's liquid asset resilience ratio.
Citius Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Citius Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Builders Capital Mortgage Corp
V:BCF
|
Canada | CA$23.53 Million |
|
Daesang Corp Preference Shares
KO:001685
|
Korea | ₩2.04 Trillion |
|
Imexhs Ltd
AU:IME
|
Australia | AU$8.36 Million |
|
IVP Limited
NSE:IVP
|
India | Rs1.87 Billion |
|
NexturnBioscience Co. Ltd
KQ:089140
|
Korea | ₩128.65 Billion |
|
Thai Capital Corporation Public Company Limited
BK:TCC
|
Thailand | ฿351.12 Million |
|
Floyd Public Company Limited
BK:FLOYD
|
Thailand | ฿176.16 Million |
|
Australian Agricultural Projects Ltd
AU:AAP
|
Australia | AU$8.54 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Citius Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CTXR market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.99 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.59 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Citius Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Citius Pharmaceuticals Inc (2011–2025)
The table below shows the annual total liabilities of Citius Pharmaceuticals Inc from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $53.41 Million | +25.52% |
| 2024-09-30 | $42.55 Million | +249.35% |
| 2023-09-30 | $12.18 Million | +15.20% |
| 2022-09-30 | $10.57 Million | +9.61% |
| 2021-09-30 | $9.65 Million | -4.52% |
| 2020-09-30 | $10.10 Million | +119.26% |
| 2019-09-30 | $4.61 Million | +44.68% |
| 2018-09-30 | $3.18 Million | +28.98% |
| 2017-09-30 | $2.47 Million | -52.37% |
| 2016-09-30 | $5.18 Million | +276.54% |
| 2015-09-30 | $1.38 Million | -40.13% |
| 2014-09-30 | $2.30 Million | +15548.54% |
| 2013-09-30 | $14.69K | -68.04% |
| 2012-09-30 | $45.98K | +91.17% |
| 2011-09-30 | $24.05K | -- |
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-… Read more